Evidence map›Paper›PMID 28260957›Full record

ReviewRisk management and healthcare policy2017

Salt reduction in China: a state-of-the-art review.

Shuai Shao, Yechu Hua, Ying Yang, Xiaojuan Liu, Jingruo Fan, An Zhang, Jingling Xiang, Mingjing Li, Lijing L Yan

Open access · goldAbstract readReview
In one paragraph

Review in Risk management and healthcare policy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 5 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 5 syntheses or guidelines pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Metabolic diseases in the East Asian populations.Nature reviews. Gastroenterology & hepatology · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 4 countries.

Shuai ShaoGlobal Health Research Center, Duke Kunshan University, Kunshan, Jiangsu, China; Duke Global Health Institute.
Yechu HuaSchool of Economics, Duke University, Durham, NC, USA.
Ying YangDepartment of Public Health, Wuhan University, Wuhan, Hubei.
Xiaojuan LiuDepartment of Biostatistics, School of Public Health, Shandong University, Jinan, Shandong, China.
Jingruo FanDepatment of Accounting, School of Business and Management, The Hong Kong University of Science and Technology, Kowloon, Hong Kong.
An ZhangDepartment of Statistics and Applied Probability, National University of Singapore, Singapore.
Jingling XiangSchool of Business, Sichuan University, Chengdu, Sichuan.
Mingjing LiDepartment of Public Health, School of Public Health and Management, Chongqing Medical University, Chongqing, China.
Lijing L YanGlobal Health Research Center, Duke Kunshan University, Kunshan, Jiangsu, China; Duke Global Health Institute.
Duke Kunshan University · CNChongqing Medical University · CNDuke University · USNational University of Singapore · SGShandong University · CNSichuan University · CNUniversity of Hong Kong · HKWuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to reveal the latest evidence on salt reduction initiatives in China in order to identify the contextual cost-effective interventions, as well as the barriers encountered during China's long march to reach its population salt reduction goal.

backgroundPopulation-based salt reduction has been considered as one of the most cost-effective strategies in the world for the prevention and control of noncommunicable diseases. China, along with its sustained economic growth, faces increasing burdens from chronic diseases such as cardiovascular and kidney diseases. With policy support and cross-sector collaboration, various salt reduction initiatives have been adopted in China in order to reduce such dietary risk, especially since the beginning of this millennium.

methodsThis study conducted structured literature reviews in both English and Chinese databases and synthesized the latest evidence on the association of salt intake and health, as well as salt intake among Chinese and population-based salt reduction strategies in China and around the world.

findingsDietary salt restriction has been found to contribute to the reduction of blood pressure among both the normotensives and hypertensives bringing associated reduced disease burdens and great public health benefits. With gender, ethnic, and regional variations, salt intake levels in the population in China are well above the recommended threshold and physiological need. Admittedly, excessive salt intake precipitates the high prevalence of hypertension and cardiovascular disease among the Chinese. Considering that the majority of the dietary salt is added during cooking in China, salt substitutes, salt restriction tools, and health education are the most common salt reduction initiatives with varying levels of effectiveness and acceptability among the Chinese population. IMPLICATION: Overwhelming evidence is in support of a well-coordinated nationwide salt restriction initiative as a key public health strategy for the prevention and control of hypertension and its related diseases. Orchestrated efforts from the government, industries, academia, health professionals, and the general public are required to achieve China's long-term goal for salt reduction.

Indexed as

Chinese populationchronic diseasehealth policyhypertensionsalt reduction

Identifiers

PMID28260957
PMCPMC5328139
OpenAlexW2591424738

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.